Pharming Group (NASDAQ:PHAR) Raised to “Hold (C-)” at Weiss Ratings

Pharming Group (NASDAQ:PHAR) was upgraded by analysts at Weiss Ratings from a “sell (d+)” rating to a “hold (c-)” rating in a research report issued on Saturday,Weiss Ratings reports.

Separately, Zacks Research cut shares of Pharming Group from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 30th. Three analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $30.00.

Pharming Group Trading Down 8.2%

NASDAQ:PHAR opened at $13.60 on Friday. The company has a current ratio of 2.79, a quick ratio of 2.07 and a debt-to-equity ratio of 0.38. Pharming Group has a 12 month low of $7.31 and a 12 month high of $17.08. The company has a market cap of $931.74 million, a PE ratio of -104.62 and a beta of 0.04. The company has a 50 day simple moving average of $14.27 and a two-hundred day simple moving average of $11.62.

Pharming Group (NASDAQ:PHAR) last posted its earnings results on Thursday, July 31st. The company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.16. Pharming Group had a negative net margin of 2.19% and a negative return on equity of 3.31%. The business had revenue of $93.20 million during the quarter, compared to the consensus estimate of $70.36 million. Pharming Group has set its FY 2025 guidance at EPS. Research analysts forecast that Pharming Group will post -0.2 earnings per share for the current year.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its holdings in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) by 8.6% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 52,147 shares of the company’s stock after purchasing an additional 4,150 shares during the period. Silverberg Bernstein Capital Management LLC owned about 0.08% of Pharming Group worth $557,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.